No Data
Should You Be Adding North China Pharmaceutical Company.Ltd (SHSE:600812) To Your Watchlist Today?
Huabei Pharmaceutical: 2024 Annual Report Summary
Huabei Pharmaceutical: 2024 Annual Report
2024 ANNUAL REPORT
2024 Annual Report Summary
North China Pharmaceutical (600812.SH): The net income in 2024 is 0.127 billion yuan, a year-on-year increase of 2496.80%.
On March 27, Gelonghui reported that North China Pharmaceutical (600812.SH) announced its annual report for 2024. During the reporting period, the company achieved revenue of 9.87 billion yuan, a year-on-year decrease of 2.48%; the net income attributable to shareholders of the listed company was 0.127 billion yuan, a year-on-year increase of 2,496.80%; the basic EPS was 0.074 yuan. The company plans to distribute a cash dividend of 0.3 yuan (including tax) for every 10 shares to all shareholders. This year, the company improved the net income attributable to shareholders of the listed company by adjusting the product structure, strengthening procurement management, reducing procurement costs, implementing lean management, and deepening cost control measures.
North China Pharmaceutical Company.Ltd (SHSE:600812) Not Doing Enough For Some Investors As Its Shares Slump 28%
